AU2007234968A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2007234968A1
AU2007234968A1 AU2007234968A AU2007234968A AU2007234968A1 AU 2007234968 A1 AU2007234968 A1 AU 2007234968A1 AU 2007234968 A AU2007234968 A AU 2007234968A AU 2007234968 A AU2007234968 A AU 2007234968A AU 2007234968 A1 AU2007234968 A1 AU 2007234968A1
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
alkylamino
aryl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007234968A
Other languages
English (en)
Inventor
Christopher Adams
Gary Michael Ksander
Julien Papillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007234968A1 publication Critical patent/AU2007234968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2007234968A 2006-03-29 2007-03-27 Organic compounds Abandoned AU2007234968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78710406P 2006-03-29 2006-03-29
US60/787,104 2006-03-29
PCT/US2007/064974 WO2007117982A2 (en) 2006-03-29 2007-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
AU2007234968A1 true AU2007234968A1 (en) 2007-10-18

Family

ID=38477291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007234968A Abandoned AU2007234968A1 (en) 2006-03-29 2007-03-27 Organic compounds

Country Status (12)

Country Link
US (1) US8153674B2 (enExample)
EP (2) EP2001866A2 (enExample)
JP (1) JP5197569B2 (enExample)
KR (1) KR20080114769A (enExample)
CN (1) CN101410389A (enExample)
AU (1) AU2007234968A1 (enExample)
BR (1) BRPI0709678A2 (enExample)
CA (1) CA2644391A1 (enExample)
ES (1) ES2442347T3 (enExample)
MX (1) MX2008012402A (enExample)
RU (1) RU2008142600A (enExample)
WO (1) WO2007117982A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
KR20090090395A (ko) * 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EA200900811A1 (ru) * 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
MX350717B (es) * 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
EP2639212B1 (en) 2012-03-13 2016-03-09 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Enantioselective organic anhydride reactions
ES2684050T3 (es) * 2014-07-24 2018-10-01 Boehringer Ingelheim International Gmbh Inhibidores de aldosterona sintasa
WO2016123275A1 (en) * 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN113767095A (zh) 2019-05-01 2021-12-07 勃林格殷格翰国际有限公司 (r)-4-溴苯磺酸(2-甲基环氧乙烷-2-基)甲酯
AU2022415313A1 (en) 2021-12-14 2024-05-02 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
JP2025540715A (ja) * 2022-11-23 2025-12-16 上▲海▼翰森生物医▲薬▼科技有限公司 ピリジン多環系化合物阻害剤、及びその製造方法と使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904300A (en) * 1987-08-26 1990-02-27 Ciba-Geigy Corp. Imidazole derivatives
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen

Also Published As

Publication number Publication date
US20090182007A1 (en) 2009-07-16
WO2007117982A2 (en) 2007-10-18
WO2007117982A3 (en) 2007-12-13
BRPI0709678A2 (pt) 2011-07-19
EP2301931B1 (en) 2013-10-16
RU2008142600A (ru) 2010-05-10
EP2301931A1 (en) 2011-03-30
JP5197569B2 (ja) 2013-05-15
EP2001866A2 (en) 2008-12-17
JP2009531457A (ja) 2009-09-03
ES2442347T3 (es) 2014-02-11
CA2644391A1 (en) 2007-10-18
MX2008012402A (es) 2008-10-09
KR20080114769A (ko) 2008-12-31
CN101410389A (zh) 2009-04-15
US8153674B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
US8153674B2 (en) Organic compounds
DK2655378T3 (en) RELATIONSHIPS AND THEIR USE AS BACE INHIBITORS
ES2404034T3 (es) Derivados de alquinilo como moduladores de receptores metabotrópicos de glutamato
MX2008002545A (es) Derivados de imidazol condensado para la inhibicion de sintasa de aldosterona y aromatasa.
EP2089367B1 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP3057586A1 (en) Bromodomain inhibitors
WO2016014975A2 (en) Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
KR101407856B1 (ko) 에티닐 유도체
JP2009538323A (ja) アルドステロン合成酵素および／または１１β−ヒドロキシラーゼ阻害剤
MX2009000107A (es) Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
EA002851B1 (ru) Хинолиновые и хиназолиновые соединения, применяемые в терапии, особенно при лечении доброкачественной гиперплазии простаты
CA2682340A1 (en) [2 , 6] naphthyridines useful as protein kinase inhibitors
JP6089104B2 (ja) アリールエチニル誘導体
EP2814814B1 (en) Imidazolylketone derivatives asd aldosterone synthase inhibitors
CA2501834A1 (en) 5-substituted 7,9-difluoro-5h-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulators
EP3044210A2 (en) Novel cytochrome p450 inhibitors and their method of use
EP3212638B1 (en) New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors
JP2003523333A (ja) ベンジルの４−イミダゾール誘導体ならびに限定されたベンジルスルホンアミド、スルファミド、尿素、カルバメート及びアミド、ならびにα１Ａ作用物質としてのそれらの使用
JP7231610B2 (ja) インドール誘導体及びその使用
CA2925294A1 (en) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
HK1190721B (en) Compounds and their use as bace inhibitors
HK1190721A (en) Compounds and their use as bace inhibitors
HK1202544B (en) Arylethynyl derivatives

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted